ORIGINAL PAPER
Botulinum toxin type A iontophoresis for post-burn hypertrophic scars: a randomised controlled trial
1
Department of Physical Therapy for Surgery, Faculty of Physical Therapy, Cairo University, Egypt
2
Department of Physical Therapy, Faculty of Allied Medical Sciences, Aqaba University of Technology, Jordan
3
Department of Plastic and General Surgery, Faculty of Medicine, Cairo University, Egypt
Submission date: 2024-02-29
Acceptance date: 2024-07-19
Publication date: 2025-09-11
Corresponding author
Hayam M. Alnawagy
Department of Physical Therapy for Surgery, Faculty of Physical Therapy, Cairo University, 7th Ahmed Elzayat St., Bein Al Sarayat, Giza, Egypt
Department of Physical Therapy for Surgery, Faculty of Physical Therapy, Cairo University, 7th Ahmed Elzayat St., Bein Al Sarayat, Giza, Egypt
Physiother Quart. 2025;33(3):55-61
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Hypertrophic scars (HSs) are caused by excessive collagen synthesis due to fibroblast proliferation. Botulinum toxin type A (BoNT-A) slows fibroblast proliferation and collagen deposition, thereby improving HSs.
Methods:
The study enrolled 76 male and female patients aged 20 to 40 years with post-burn HSs (PBHSs) who were randomly allocated into experimental and control groups and followed a three-month program. The experimental group received BoNT-A iontophoresis and traditional physical therapy (TPT), while the control group only received the TPT program. High-resolution ultrasonography assessed scar thickness, while the Patient Scar Assessment Scale (PSAS) and Observer Scar Assessment Scale (OSAS) evaluated scar characteristics at the end of the three-month treatment (post I) and at the six-month follow-up (post II). A mixed-model multivariate analysis of variance (MANOVA) examined the impact of therapy on scar thickness and the Patient and Observer Scar Assessment Scale (POSAS).
Results:
Scar thickness decreased in the experimental group compared to the control group at post-I and post-II, with effect sizes 0.77 and 1.45, respectively. Furthermore, there was a significant decrease in OSAS total score and general opinion for the experimental group compared to the control group at post-I and post-II, with effect sizes of 0.95 and 2.02, and 0.53 and 1.30, respectively. PSAS total score and general opinion decreased for the experimental group compared to the control group at post-I and post-II, with effect sizes of 0.89 and 1.95, and 0.81 and 1.39, respectively.
Conclusions:
BoNT-A iontophoresis had a long-lasting effect on reducing HS thickness and improving its characteristics. The process has several advantages, such as being noninvasive, painless, and externally controlled.
Hypertrophic scars (HSs) are caused by excessive collagen synthesis due to fibroblast proliferation. Botulinum toxin type A (BoNT-A) slows fibroblast proliferation and collagen deposition, thereby improving HSs.
Methods:
The study enrolled 76 male and female patients aged 20 to 40 years with post-burn HSs (PBHSs) who were randomly allocated into experimental and control groups and followed a three-month program. The experimental group received BoNT-A iontophoresis and traditional physical therapy (TPT), while the control group only received the TPT program. High-resolution ultrasonography assessed scar thickness, while the Patient Scar Assessment Scale (PSAS) and Observer Scar Assessment Scale (OSAS) evaluated scar characteristics at the end of the three-month treatment (post I) and at the six-month follow-up (post II). A mixed-model multivariate analysis of variance (MANOVA) examined the impact of therapy on scar thickness and the Patient and Observer Scar Assessment Scale (POSAS).
Results:
Scar thickness decreased in the experimental group compared to the control group at post-I and post-II, with effect sizes 0.77 and 1.45, respectively. Furthermore, there was a significant decrease in OSAS total score and general opinion for the experimental group compared to the control group at post-I and post-II, with effect sizes of 0.95 and 2.02, and 0.53 and 1.30, respectively. PSAS total score and general opinion decreased for the experimental group compared to the control group at post-I and post-II, with effect sizes of 0.89 and 1.95, and 0.81 and 1.39, respectively.
Conclusions:
BoNT-A iontophoresis had a long-lasting effect on reducing HS thickness and improving its characteristics. The process has several advantages, such as being noninvasive, painless, and externally controlled.
REFERENCES (29)
1.
Shirakami E, Yamakawa S, Hayashida K. Strategies to prevent hypertrophic scar formation: a review of therapeutic interventions based on molecular evidence. Burns Trauma. 2020;8:tkz003; doi: 10.1093/burnst/tkz003.
2.
van Baar ME. Epidemiology of scars and their consequences: burn scars. In: Téot L, Mustoe TA, Middelkoop E, Gauglitz GG (eds.). Textbook on Scar Management. State of the Art Management and Emerging Technologies. Cham: Springer; 2020, pp. 37–43.
3.
Lee HJ, Jang YJ. Recent understandings of biology, prophylaxis and treatment strategies for hypertrophic scars and keloids. Int J Mol Sci. 2018;19(3); doi: 10.3390/ijms19030711.
4.
Ghazawi FM, Zargham R, Gilardino MS, Sasseville D, Jafarian F. Insights into the Pathophysiology of hypertrophic scars and keloids: how do they differ?. Adv Skin Wound Care. 2018;31(1):582–95.
5.
Robinson AJ, Khadim MF, Khan K. Keloid scars and treatment with botulinum toxin type A: the Belfast experience. J Plast Reconstr Aesthet Surg. 2013;66(3):439–40; doi: 10.1016/j.bjps.2012.08.042.
6.
Carrero LMK, Ma W-W, Liu H-F, Yin X-F, Zhou B-R. Botulinum toxin type A for the treatment and prevention of hypertrophic scars and keloids: updated review. J Cosmet Dermatol. 2019;18(1):10–5; doi: 10.1111/jocd.12828.
7.
Samizadeh S, De Boulle K. Botulinum neurotoxin formulations: overcoming the confusion. Clin Cosmet Investig Dermatol. 2018;11:273–87; doi: 10.2147/CCID.S156851.
8.
Montaser-Kouhsari L, Zartab H, Fanian F, Noorian N, Sadr B, Nassiri-Kashani M, Firoos A. Comparison of intradermal injection with iontophoresis of abobotulinum toxin A for the treatment of primary axillary hyperhidrosis: a randomized, controlled trial. J Dermatol Treat. 2014;25(4):337–41; doi: 10.3109/09546634.2012.739679.
9.
Roustit M, Blaise S, Cracowski J-L. Trials and tribulations of skin iontophoresis in therapeutics. Br J Clin Pharmacol. 2014;77(1):63–71; doi: 10.1111/bcp.12128.
10.
Tawfik AA, Ali RA. Evaluation of botulinum toxin type A for treating post-burn hypertrophic scars and keloid in children: an intra-patient randomised controlled study. J Cosmet Dermatol. 2023;22(4):1256–60; doi: 10.1111/jocd.15634.
11.
Sheikh NK, Dua A. Iontophoresis Analgesic Medications. StatPearls. Treasure Island (FL) ineligible companies. Disclosure: Anterpreet Dua declares no relevant financial relationships with ineligible companies. StatPearls Publishing; 2024.
12.
Elshahed AR, Elmanzalawy KS, Shehata H, ElSaie ML. Effect of botulinum toxin type A for treating hypertrophic scars: a split-scar, double-blind, randomized controlled trial. J Cosmet Dermatol. 2020;19(9):2252–8; doi: 10.1111/jocd.13627.
13.
Kim HI, Kim HS, Yi HS, Kim YS. Scar assessment after fractional CO2 laser resurfacing using a questionnaire. Med Lasers. 2022;11(3):166–72; doi: 10.25289/ML.2022.11.3.166.
14.
Van de Kar AL, Corion LUM, Smeulders MJC, Draaijers LJ, van der Horst CMAM, Van Zuijlen PPM. Reliable and feasible evaluation of linear scars by the Patient and Observer Scar Assessment Scale. Plast Reconstr Surg. 2005;116(2):514–22; doi: 10.1097/01.prs.0000172982.43599.d6.
15.
Nossier AA, Esraa AA, Saied M, Samia M. Validity and reliability of Arabic version of the patient and observer scar assessment scale with burned patients. Med J Cairo Univ. 2018;86:2311–6.
16.
Lee SY, Cho YS, Kim L, Joo SY, Seo CH. The intra-rater reliability and validity of ultrasonography in the evaluation of hypertrophic scars caused by burns. Burns. 2023;49(2):344–52; doi: 10.1016/j.burns.2022.03.016.
17.
Kisner C, Colby LA, Borstad J. Therapeutic Exercise. Foundations and Techniques. Philadelphia: F.A. Davis Company; 2017.
18.
Téot L, Mustoe TA, Middelkoop E, Gauglitz GG (eds.). Textbook on Scar Management. State of the Art Management and Emerging Technologies. Cham: Springer; 2020; doi: 10.1007/978-3-030-44766-3.
19.
Oliveira R, Ferreira J, Azevedo LF, Almeida IF. An overview of methods to characterize skin type: focus on visual rating scales and self-report instruments. Cosmetics. 2023;10(1):14; doi: 10.3390/cosmetics10010014.
20.
Khatery BH, Hussein HA, Abd-el-Raheem TA, El Hanbuli HM, Yassen NN. Assessment of intralesional injection of botulinum toxin type A in hypertrophic scars and keloids: clinical and pathological study. Dermatol Ther. 2022;35(10):e15748; doi: 10.1111/dth.15748.
21.
Hu L, Zou Y, Chang S-J, Qiu Y, Chen H, Gang M, Jin Y, Lin X. Effects of botulinum toxin on improving facial surgical scars: a prospective, split-scar, double-blind, randomized controlled trial. Plast Reconstr Surg. 2018;141(3):646–50; doi: 10.1097/PRS.0000000000004110.
22.
Shaarawy E, Hegazy RA, Hay RMA. Intralesional botulinum toxin type A equally effective and better tolerated than intralesional steroid in the treatment of keloids: a randomized controlled trial. J Cosmet Dermatol. 2015;14(2):161–6; doi: 10.1111/jocd.12134.
23.
Austin E, Koo E, Jagdeo J. The cellular response of keloids and hypertrophic scars to botulinum toxin A: a comprehensive literature review. Dermatol Surg. 2018;44(2):149–57; doi: 10.1097/DSS.0000000000001360.
24.
Manda P, Angamuthu M, Hiremath SR, Raman V, Murthy SN. Iontophoretic drug delivery for the treatment of scars. J Pharmaceutical Sci. 2014;103(6):1638–42; doi: 10.1002/jps.23946.
25.
Andrade JFM, Cunha-Filho M, Gelfuso GM, Gratieri T. Iontophoresis for the cutaneous delivery of nanoentraped drugs. Expert Opinion Drug Delivery. 2023: 20(6):785–98; doi: 10.1080/17425247.2023.2209719.
26.
Hasan M, Khatun A, Kogure K. Iontophoresis of biological macromolecular drugs. Pharmaceutics. 2022;14:525; doi: 10.3390/pharmaceutics14030525.
27.
Mohamed SA, Khalaf MM, Ibrahim IG, Elnour NHA. Postburn hypertrophic scar response to potassium iodide iontophoresis. Med J Cairo Univ. 2017;85(7):2527–32.
28.
Ghareeb MAE-N, Othman EM, Awny S, Abd El Baky AM. Effect of hydrocortisone iontophoresis versus hydrocortisone phonophoresis on post-surgical scar: a prospective randomized controlled trial. Eur Chemical Bull. 2023;12(Spec issue 4):6033–42.
29.
Dardas A, Bae GH, Yule A, Wright J, Straughn N, Day CS. Acetic acid iontophoresis for recalcitrant scarring in post-operative hand patients. J Hand Ther. 2014;27(1):44–8; doi: 10.1016/j.jht.2013.10.008.
Share
RELATED ARTICLE
| eISSN: | 2544-4395 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
